GLP-1s, Eye Disease & EU Pharma: News Roundup
- kennedy Jr.recently stated the Food and Drug Administration will seek methods to accelerate the approval process for rare disease treatments.
- Kennedy's remarks came during an FDA meeting focused on cell and gene therapies.
- Separately, a recent study published in JAMA Ophthalmology suggests a small but elevated risk of age-related macular degeneration (AMD) among diabetes patients using GLP-1 drugs.
GLP-1s and AMD Risk Examined; FDA to Expedite Rare Disease Treatments
U.S. Health and Human Services Secretary Robert F. kennedy Jr.recently stated the Food and Drug Administration will seek methods to accelerate the approval process for rare disease treatments. The goal is to eliminate obstacles hindering their market entry.
Kennedy’s remarks came during an FDA meeting focused on cell and gene therapies. Panelists at the meeting emphasized the need for quicker regulatory pathways, cautioning that other nations could surpass the U.S. in drug advancement. The meeting included industry executives,researchers,and FDA officials,such as Vinay prasad,head of the FDA’s Center for Biologics Evaluation and Research.
Separately, a recent study published in JAMA Ophthalmology suggests a small but elevated risk of age-related macular degeneration (AMD) among diabetes patients using GLP-1 drugs. This adds to existing concerns regarding eye health and these medications.
The observational study, drawing data from nearly 140,000 patients in Canada, revealed that after one year, the incidence of neovascular AMD was twice as high in GLP-1 users (0.2%) compared to non-users (0.1%).The participants, averaging 66 years old, were matched for socioeconomic status and various health conditions.
AMD is a primary cause of irreversible blindness in older adults.Researchers, aware of other potential eye issues related to GLP-1s, investigated the possible link between these drugs and AMD.
What’s next
The FDA’s efforts to streamline approvals could bring faster access to treatments for rare diseases. Further research is needed to fully understand the connection between GLP-1 drugs and the risk of age-related macular degeneration.